Cipla shares dropped 2.93% or ₹38.20 to ₹1,267.70 on the NSE as of 9:25 AM IST on April 24, touching an intraday low of ₹1,254.10 in early trade, after it emerged that the FDA has placed an import alert on Pharmathen’s Rodopi facility in Greece — the partner manufacturing unit that produces Lanreotide Injection for Cipla’s US business. Market capitalisation stands at ₹1.02 lakh crore with the stock trading at a PE of 22.49 and a dividend yield of 1.03%.
The import alert is a direct and material revenue risk. Analysts had been estimating $50-60 million in Lanreotide Injection revenue for Cipla in FY27 and $100 million in FY28. Those estimates are now effectively out of the picture for as long as the import alert remains in force.
What the FDA Import Alert Means
An FDA import alert is one of the most serious regulatory actions the US food and drug regulator can take against a manufacturing facility — it means the FDA has determined that products from the flagged unit may be detained at the US border without physical examination. The practical consequence is that Lanreotide Injections manufactured at Pharmathen’s Rodopi, Greece facility cannot be imported into the United States until the import alert is resolved through a remediation process that satisfies FDA inspectors.
For Cipla, which does not manufacture Lanreotide itself but sources it through its partnership with Pharmathen International S.A. specifically from the Rodopi facility, the import alert creates an immediate supply chain disruption for a product that was supposed to be one of its key US revenue drivers in FY27 and FY28.
The Revenue Impact — Analyst Estimates Gone
The analyst community had built meaningful expectations around Lanreotide Injection as a US revenue contributor for Cipla. With $50-60 million estimated for FY27 and $100 million for FY28, Lanreotide was expected to be a significant offset to the gRevlimid cliff that Cipla has been navigating — the gradual erosion of the high-margin Lenalidomide exclusivity revenue that has been supporting US profitability.
Those estimates are now effectively withdrawn from models pending clarity on the import alert timeline. FDA import alerts can take months to years to resolve depending on the nature and extent of the compliance failures identified at the facility — and Pharmathen’s Rodopi will need to demonstrate corrective action to the FDA’s satisfaction before the alert is lifted.
Citi, which had just reiterated a Buy on Cipla with a target of ₹1,530 citing the Ventolin HFA approval as a positive milestone, had specifically flagged Lanreotide disruptions as a risk in its note — stating that the Ventolin HFA revenue of $50-70 million would help “offset potential declines in US sales stemming from Lanreotide disruptions.” The import alert confirms those disruptions are now a reality rather than a risk.
The Irony of Today’s Session for Cipla
The timing of the import alert landing on the same day as the Ventolin HFA generic approval was being celebrated as a pipeline confidence booster is notable. Citi’s thesis — that the respiratory approval would offset Lanreotide weakness — has been tested in the same session in which it was articulated. The net effect is a stock that is falling sharply despite having a positive regulatory event on one product because the negative regulatory event on another product is larger in revenue terms and more immediate in impact.
Ventolin HFA is estimated to contribute $50-70 million in revenue over time. Lanreotide was expected to contribute $50-60 million in FY27 and $100 million in FY28. The Lanreotide loss is approximately equal to the Ventolin HFA gain in FY27 and significantly larger in FY28 — making the net regulatory news for Cipla’s US business on Thursday a wash at best and a negative at worst.
What to Watch Next
The key questions for Cipla investors from this point are how long the import alert on Pharmathen’s Rodopi facility takes to resolve, whether Cipla has or can develop an alternative supply arrangement for Lanreotide from a different manufacturing partner with FDA-compliant status, and how much of the FY27 and FY28 US revenue estimate Street models need to be revised downward as a result.
The broader concern — which Citi had flagged and which the Lanreotide disruption now amplifies — is that the gRevlimid cliff needs to be offset by multiple new product approvals and launches simultaneously. Ventolin HFA is one offset. Lanreotide was supposed to be another. With one of those two now impaired, the offset burden falls more heavily on generic Advair, the undisclosed respiratory product and the Teduglutide biosimilar that Citi flagged as upcoming key launches to watch.
At ₹1,267.70 with the day range touching a low of ₹1,254.10 — against a year range of ₹1,165.70 to ₹1,673 — the stock is trading meaningfully above its 52-week low, which provides some valuation support even as the Lanreotide news processes through the market today.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers are advised to consult a SEBI-registered financial advisor before making investment decisions. Stock prices are indicative and subject to change.